Conditions where inhibition of gastric acid secretion may be beneficial, including aspiration syndromes, dyspepsia, GERD, PUD & Zollinger-Ellison syndrome.
40 mg over 20-30 min by IV infusion. To be given on a short-term basis in patients who are unsuited to receive oral therapy. May also be given by slow IV inj.
May affect exposure w/ CYP2C19 & CYP3A4 inhibitors or inducers. May alter metabolism of some drugs metabolised by CYP2C19 & CYP3A4 isoenzymes. May prolong the elimination of diazepam, phenytoin, & warfarin. Reduce the absorption of drugs eg, dasatinib, ketoconazole & itraconazole. Increased plasma conc of both drugs w/ voriconazole. Reduce exposure of atazanavir.
A02BC01 - omeprazole ; Belongs to the class of proton pump inhibitors. Used in the treatment of peptic ulcer and gastro-oesophageal reflux disease (GERD).
Sign Out
